Drugs in development · updated 11 November 2026
Nezutatug: clinical trials and development status
Other names and codes: HMBD-001
As of 11 November 2026 Nezutatug is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 15 diseases. The most advanced phase is I–II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3), with potential antineoplastic activity. Upon administration, nezutatug targets and binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Non-small-cell lung carcinoma | I–II | 3 | NCT05910827 |
| Pancreatic neoplasm | I–II | 2 | NCT05057013 |
| Bladder neoplasm | I–II | 1 | NCT05057013 |
| Castration-resistant prostatic neoplasm | I–II | 1 | NCT05057013 |
| Endometrial neoplasm | I–II | 1 | NCT05057013 |
| Esophageal neoplasm | I–II | 1 | NCT05057013 |
| Head and neck squamous cell carcinoma | I–II | 1 | NCT05910827 |
| Hepatocellular carcinoma | I–II | 1 | NCT05057013 |
| Melanoma | I–II | 1 | NCT05057013 |
| Ovarian neoplasm | I–II | 1 | NCT05057013 |
| Squamous cell carcinoma | I–II | 1 | NCT05910827 |
| Stomach neoplasm | I–II | 1 | NCT05057013 |
| Triple-negative breast neoplasm | I–II | 1 | NCT05057013 |
| Uterine cervix neoplasm | I–II | 1 | NCT05057013 |
| Metastasis | I | 1 | NCT05919537 |
Sites in Europe
4 sites of the active trials in one European country, 0 recruiting.
- United Kingdom4
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Nezutatug
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.